Scroll back to top

VistaSeq Hereditary Cancer Panel without BRCA

CPT: 81201; 81203; 81292; 81294; 81295; 81297; 81298; 81300; 81317; 81319; 81321; 81323; 81403; 81404(x2); 81405(x3); 81406(x4); 81408; 81479

Test Includes

The following genes are assessed: APC, ATM, BARD1, BMPR1A, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FAM175A, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRKAR1A, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53.

Special Instructions

A clinical questionnaire should be submitted with all specimens

Expected Turnaround Time

24 - 28 days Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Specimen Requirements


Whole blood, saliva collected in an Oragene Dx collection kit


10 mL whole blood, 2 mL saliva

Minimum Volume

7 mL whole blood, 0.5 mL saliva


Lavender-top (EDTA) tube or yellow-top (ACD) tube


Blood is collected by routine phlebotomy. Saliva is collected by spitting into the provided container until it reaches the fill line.

Storage Instructions

Maintain specimen at room temperature

Causes for Rejection

Frozen specimen; leaking tube; clotted specimen; grossly hemolyzed specimen; incorrect anticoagulant

Test Details


The VistaSeq℠ Hereditary Cancer Panel Without BRCA provides an assessment of inherited genetic mutations within a panel of 25 genes known to be associated with hereditary cancer syndromes. The test is intended for individuals who have already had a BRCA1 and BRCA2 gene assessment, but for whom results of that testing were negative and/or personal or family history warrant assessment of additional genes.


Each gene sequence is interpreted independently of all other gene sequences. However, variants in different genes may sometimes interact to cause or modify a typically monogenic disease phenotype. It cannot be excluded that pathogenic variants were missed due to limitations inherent in the methodologies used here. In addition, the presence of an inherited cancer syndrome due to a different genetic cause can also not be ruled out. Any interpretation given here should be clinically correlated with available information about presentation and relevant family history of the patient. This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).


Next generation sequencing, array-based comparative genomic hybridization (aCGH), and multiplex ligation-dependent probe amplification (MLPA) platforms. The entire coding regions, as well as all flanking noncoding regions, of 25 cancer genes known to be involved in the development and progression of cancers is analyzed by next generation sequencing. Flanking regions for all genes include +/– 20 bp and +/– 10 bp. Copy number variations are assessed by aCGH or MLPA to detect deletions and duplications. BRCA1 and BRCA2 genes are not included in this test.


Daly MB, Axilbund JE, Buys S, et al. Clinical practice guidelines in oncology. Genetic/familial high-risk assessment: Breast and ovarian. J Natl Compr Canc Netw. 2010 May; 8(5):562-594. PubMed 20495085 LaDuca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: Analysis of more than 2,000 patients. Genet Med. 2014 Nov; 16(11):830-837. PubMed 24763289 Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. Working Group of the American College of Medical Genetics and Genomics Laboratory Quality Assurance Committee. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013 Sep; 15(9):733-747. PubMed 23887774 Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer.2015 Jan 1; 121(1):25-33. PubMed 25186627